Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma

被引:65
|
作者
Wu, Jian-Min [1 ]
Skill, Nicholas J. [1 ]
Maluccio, Mary A. [1 ]
机构
[1] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA
关键词
hepatitis C virus (HCV); lipid metabolism; hepatic steatosis; hepatocellular carcinoma (HCC); FATTY-ACID SYNTHASE; VIRUS CORE PROTEIN; COA-CARBOXYLASE-ALPHA; GENE-EXPRESSION; RECEPTOR-ALPHA; STEATOSIS; CANCER; LIVER; PROGRESSION; GENOTYPE;
D O I
10.1111/j.1477-2574.2010.00207.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Lipids are linked to many pathological processes including hepatic steatosis and liver malignancy. This study aimed to explore lipid metabolism in hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). Methods: Serum lipids were measured in normal, HCV and HCV-HCC patients. Whole-genome microarray was performed to identify potential signature genes involved in lipid metabolism characterizing normal vs. HCV vs. HCV-HCC conditions. Results: Serum cholesterol was significantly reduced in HCV and HCV-HCC patients compared with normal controls, whereas there was no difference in glucose and triglycerides. Microarray analysis identified 224 probe sets with known functional roles in lipid metabolism (ANOVA, 1.5-fold, P <= 0.001). Gene-mediated fatty acid (FA) de novo synthesis and uptake were upregulated in HCV and this upregulation was further enhanced in HCC. Genes involved in FA oxidation were downregulated in both the HCV and HCC groups. The abnormality of cholesterol metabolism in HCV was associated with downregulation of genes involved in cholesterol biosynthesis, absorption and transportation and bile acid synthesis; this abnormality was further intensified in HCC. Conclusions: Our data support the notion that HCV-related lipid metabolic abnormalities may contribute to hepatic steatosis and the development of cancer. Identification of these aberrations would stratify patients and improve treatment algorithms.
引用
收藏
页码:625 / 636
页数:12
相关论文
共 50 条
  • [1] Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics
    Li, Zhao
    Guan, Ming
    Lin, Yu
    Cui, Xiao
    Zhang, Yangyang
    Zhao, Zhenwen
    Zhu, Jiye
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)
  • [2] Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Plasma Metabolomics and Lipid Profiling
    Patterson, Andrew D.
    Maurhofer, Olivier
    Beyoglu, Diren
    Lanz, Christian
    Krausz, Kristopher W.
    Pabst, Thomas
    Gonzalez, Frank J.
    Dufour, Jean-Francois
    Idle, Jeffrey R.
    CANCER RESEARCH, 2011, 71 (21) : 6590 - 6600
  • [3] Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review
    Hu, Bo
    Lin, Jian-Zhen
    Yang, Xiao-Bo
    Sang, Xin-Ting
    CELL PROLIFERATION, 2020, 53 (03)
  • [4] Hepatocellular Carcinoma in a Patient With Hepatitis C and No Evidence of Cirrhosis
    Cochrane, Justin
    Anderson, Jon
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S323 - S323
  • [5] ABERRANT PORPHYRIN METABOLISM IN HEPATOCELLULAR-CARCINOMA
    UDAGAWA, M
    HORIE, Y
    HIRAYAMA, C
    BIOCHEMICAL MEDICINE, 1984, 31 (02): : 131 - 139
  • [6] Role of lipid metabolism in hepatocellular carcinoma
    Cheng, Yulin
    He, Jun
    Zuo, Bin
    He, Yang
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [7] Hepatitis C and hepatocellular carcinoma
    DiBisceglie, AM
    HEPATOLOGY, 1997, 26 (03) : S34 - S38
  • [8] Hepatitis C and hepatocellular carcinoma
    Yao F.
    Terrault N.
    Current Treatment Options in Oncology, 2001, 2 (6) : 473 - 483
  • [9] Hepatitis C and hepatocellular carcinoma
    Leach B.H.
    Schwartz J.M.
    Current Hepatitis Reports, 2007, 6 (3) : 87 - 90
  • [10] Hepatitis C and hepatocellular carcinoma
    Underwood, JCE
    RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 173 - 177